Gordon Vansant, BSB, PhD

Dr. Vansant received his BS in Biochemistry from East Carolina University in North Carolina and his PhD in Molecular Biology from the University of Hawaii in Oahu.  He followed his doctorate work with two post-doctorate fellowships, one at Sidney Kimmel Cancer Center and one at University of California, both in San Diego.

Dr. Vansant then started his career at The Immune Response Corporation where he worked on discovery projects for neurological disorders and neurotrauma and then at Burstein Labs on unique PCR platform development.  Both included collaboration with Dr. Kary Mullis.  Dr. Vansant then joined Althea, where he had roles of increasing responsibility as Director of Technology Development, Analytical Services, and then as Director of Business Development. Other successful business development roles were at Metabolon, Somalogic, EPIC Sciences, Interpace, ResearchDx and Biofluidica. Dr. Vansant has over 20 years of experience in nucleic acid, proteomic and biochemical analysis. His scientific and business development roles have been in GLP certified, and CLIA / CAP accredited CRO laboratories.  His work has included technology transfer and the development of innovative technologies for biomarker and drug development support, with an emphasis on oncology.